Merck's first cGMP Oligonucleotide Manufacturing suite

14 March 2024

In this video, Merck announces the opening of its company's first cGMP Oligonucleotide Manufacturing suite in St. Louis, MO, USA. This expansion broadens their oligo offerings to include cGMP quality oligos tailored for the diagnostic and clinical markets. The benefits of oligos made under these quality and manufacturing systems include controlled and validated processes, extensive materials traceability, batch-to-batch consistency, reproducible results, and bulk amounts.